BackBrightPath Biotherapeutics , Ltd. Overview

BrightPath Biotherapeutics , Ltd. Current Assets

Track BrightPath Biotherapeutics , Ltd.'s current assets ($2B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$1.97B
↑ 69.96% YoYΔ $812.51M vs prior year quarter

Peer trimmed avg / median

Loading

BrightPath Biotherapeutics , Ltd. Current Assets History

Loading

BrightPath Biotherapeutics , Ltd. vs. peers: Current Assets Comparison

Loading

BrightPath Biotherapeutics , Ltd. Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

BrightPath Biotherapeutics , Ltd. (4594.T) FAQ

As of the most recent data (June 2026), 4594.T shows a current assets of $2B. That compares with $1.2B in the prior-year period — up 70.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 4594.T's current assets is now $2B (was $1.2B) — a 70.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether BrightPath Biotherapeutics , Ltd. is outperforming or lagging.

Tracking 4594.T's current assets over time shows whether BrightPath Biotherapeutics , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $2B That compares with $1.2B in the prior-year period — up 70.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current assets page, Stockcircle has BrightPath Biotherapeutics , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $2B) with ownership activity and broader fundamentals.

BrightPath Biotherapeutics , Ltd.'s current assets is $2B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.